Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial

Jacqueline G. O'Leary, Jessica L. Chan, Cory M. McMahon, Raymond T. Chung

Research output: Contribution to journalArticle

93 Scopus citations

Abstract

Cholesterol biosynthesis is an integral part of HCV RNA replication. Not only does HCV RNA replicate on lipid rafts, but it also requires cholesterol intermediates to replicate. In addition, it has been shown in vitro that several HMG-CoA reductase inhibitors can decrease HCV RNA replication by ≥ 1 log. Therefore, we designed a clinical trial to evaluate the effect of atorvastatin on HCV RNA levels. In this prospective clinical trial, where patients served as their own control, 10 HCV-infected patients who required treatment for high cholesterol were given 20 mg atorvastatin per day. Although serum cholesterol and LDL predictably decreased significantly, there was no statistically significant change in week 4 and week 12 HCV RNA levels compared to pretreatment HCV RNA levels by the paired Student t test. It is unclear whether the addition of an HMG-CoA reductase inhibitor to interferon or a more potent inhibitor of cholesterol biosynthesis may be required to inhibit HCV RNA replication in vivo. In conclusion, atorvastatin, and likely all HMG-CoA reductase inhibitors, does not inhibit HCV RNA replication in vivo at conventional doses.

Original languageEnglish (US)
Pages (from-to)895-898
Number of pages4
JournalHepatology
Volume45
Issue number4
DOIs
StatePublished - Apr 1 2007

    Fingerprint

ASJC Scopus subject areas

  • Hepatology

Cite this